Diosmin + Hesperidin (Daflon® 1000) For Heavy, Painful legs and Varicose Veins
Recommended, non prescription brand for treating chronic venous insufficiency symptoms 1
How does Diosmin + Hesperidin (Daflon® 1000) work?
Venoactive treatments, like Diosmin + Hesperidin (Daflon® 1000), are designed to help improve our leg vein health by strengthening the tone of our veins, which continue to weaken as chronic venous insufficiency progresses.
Diosmin + Hesperidin (Daflon® 1000) has a dual mechanism of action; its venous anti-inflammatory action venoprotective reduces pain and swelling; it also protects the capillaries or tiny blood vessels to improve microcirculation and venous tone for better vein health and relief of symptoms such as leg pain, and swelling. 2
Tackle leg pain from the inside
Diosmin + Hesperidin (Daflon® 1000) is a clinically proven, effective and convenient oral treatment derived from immature oranges and specially formulated for maximum absorption. 2
This improved absorption means Diosmin + Hesperidin (Daflon® 1000) can get to the root of the problem and effectively treat veins from the inside, improving the tone of veins, potentially protecting against disease progression and providing relief from heavy, painful leg symptoms. 2
Demonstrated effect of Diosmin + Hesperidin (Daflon® 1000) Over 8 weeks
4 weeks 4
8 weeks 4
Leg pain
50%
63%
Sensation of heaviness
50%
65%
Sensation of swelling
50%
63%
Relieves Symptoms
Recommended, non prescription brand for treating chronic venous insufficiency symptoms. 1
Clinical Studies have shown that Diosmin + Hesperidin (Daflon® 1000) can reduce leg pain and the sensations of heaviness and swelling by up to 50% after only one month of use. These figures were even higher after two months of treatment.
To benefit from your Diosmin + Hesperidin (Daflon® 1000) treatment, you should take your medication as recommended. Be sure to monitor your condition closely and speak with a health care professional if you have any concerns.
Why you should treat early
Diosmin + Hesperidin (Daflon® 1000) is a venoactive drug treatment which, thanks to its venous anti-inflammatory and venoprotective actions, can potentially prevent the development and progression of chronic venous insufficiency. 2 This progressive condition requires treatment from the earliest stages of disease. Lifestyle changes, compression stockings and using a venoactive drug treatment that tackles the root cause of the problem can help alleviate painful symptoms. By treating early with Diosmin + Hesperidin (Daflon® 1000) you can help relieve symptoms and prevent them getting worse. 5
Convenient Oral Dosing
Diosmin + Hesperidin (Daflon® 1000) can be used from the earliest signs and prevents the development and progression of the disease. 2
Diosmin + Hesperidin (Daflon® 1000). Ongoing treatment for mild-to-moderate Chronic Venous InsufficiencyOne Tablet Once a DayBest results achieved at 2 months
Diosmin + Hesperidin (Daflon® 1000). Naturally sourced, scientifically prepared.
The active ingredient in Diosmin + Hesperidin (Daflon® 1000) is a micronized purified flavonoid fraction (MPFF) 6 containing 90% diosmin and 10% other flavonoids expressed as hesperidin.
Diosmin + Hesperidin (Daflon® 1000)’s flavonoids are extracted from immature oranges that are rich in these naturally occurring plant chemicals. The compounds undergo a process of purification and refinement where the particles are made to collide with each other at high speeds (micronization), reducing them to tiny particles, less than 2 μm in size (micronized). These smaller particles are absorbed twice as easily by the body and are a key ingredient of Diosmin + Hesperidin (Daflon® 1000)’s success as a treatment for improving vein health and tone in Chronic Venous Insufficiency and Hemorrhoids. 6
Safety Information:
Diosmin + Hesperidin (Daflon® 1000)
COMPOSITION: Micronized, purified flavonoid fraction 1000 mg: 900 mg diosmin; 100 mg flavonoids expressed as hesperidin.
INDICATIONS: Treatment of organic and idiopathic chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs; pain; nocturnal cramps. Treatment of hemorrhoids and acute hemorrhoidal attacks.
DOSAGE AND ADMINISTRATION: In venous disease: 1000 mg daily. In acute hemorrhoidal attacks: 3000 mg per day for the first 4 days, then 2000 mg per day for 3 days. Method of administration: Oral route.
CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients.
WARNINGS: The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. The treatment must be short-term. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed. Excipients: sodium-free.
INTERACTION: None.
PREGNANCY/LACTATION: Treatment should be avoided.
UNDESIRABLE EFFECTS: Common: diarrhea, dyspepsia, nausea, vomiting. Uncommon: colitis. Rare: dizziness, headache, malaise, rash, pruritus, urticaria. Frequency not known: abdominal pain, isolated face, lip, eyelid edema. Exceptionally, Quincke’s edema.
PROPERTIES: Vascular protector and venotonic. Daflon acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance.
PRESENTATION: Pack of 30 film-coated tablets.
STORAGE: Store at temperatures not exceeding 30°C.
For suspected adverse drug reaction, report to the FDA at www.fda.gov.ph.
SERVIER PHILIPPINES, INC. Unit AD, 11th Floor, 8 Rockwell, Hidalgo Drive, Rockwell Center, Makati City, 1210.
Further information available upon request.
Diosmin + Hesperidin (Daflon® 500)
COMPOSITION: Micronized, purified flavonoid fraction 500 mg: 450 mg diosmin; 50 mg flavonoids expressed as hesperidin.
INDICATIONS: Treatment of organic and idiopathic chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs; pain; nocturnal cramps. Treatment of hemorrhoids and acute hemorrhoidal attacks.
DOSAGE AND ADMINISTRATION: In venous disease: 1000 mg daily. In acute hemorrhoidal attacks: 3000 mg per day for the first 4 days, then 2000 mg per day for 3 days. Method of administration: Oral route.
CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients.
WARNINGS: The administration of this product for the symptomatic treatment of acute hemorrhoids does not preclude treatment for other anal conditions. The treatment must be short-term. If symptoms do not subside promptly, a proctological examination should be performed and the treatment should be reviewed. Excipients: sodium-free.
INTERACTION: None.
PREGNANCY/LACTATION: Treatment should be avoided.
UNDESIRABLE EFFECTS: Common: diarrhea, dyspepsia, nausea, vomiting. Uncommon: colitis. Rare: dizziness, headache, malaise, rash, pruritus, urticaria. Frequency not known: abdominal pain, isolated face, lip, eyelid edema. Exceptionally, Quincke’s edema.
PROPERTIES: Vascular protector and venotonic. Daflon acts on the return vascular system: it reduces venous distensibility and venous stasis; in the microcirculation, it normalizes capillary permeability and reinforces capillary resistance.
PRESENTATION: Pack of 30 film-coated tablets.
STORAGE: Store at temperatures not exceeding 30°C.
For suspected adverse drug reaction, report to the FDA at www.fda.gov.ph.
SERVIER PHILIPPINES, INC. Unit AD, 11th Floor, 8 Rockwell, Hidalgo Drive, Rockwell Center, Makati City, 1210.
Further information available upon request.
References:
- IQVIA Daflon sales data MAT Q2 2021
- Adapted from Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol. 2018;37(3):181-254.1
- Garner RC, Garner JV, Gregory S, Whattam M, Calam A, Leong D. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci. 2002;91:32-40.
- Gilly R, Pillion G, Frileux C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology. 1994;9:67-70.
- Pascarella L, Lulic D, Penn AH, et al. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg. Eur J Vasc Endovasc Surg. 2008;35(1):102-110.
- Summary of Product Characteristics Daflon
2025